GSK files Votrient in ovarian cancer in the EU
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has filed its targeted anticancer Votrient (pazopanib) in the EU for a third indication, the maintenance treatment of women with Stage II-IV ovarian, fallopian tube or primary peritoneal cancer who have not progressed after receiving first-line chemotherapy. This marks the first filing for this use, but the company adds that it is working on submissions in other countries worldwide.
You may also be interested in...
Novavax’s COVID-19 Vaccine Boost From First Phase I Data
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
Acadia Hit By Two Surprise Disappointments With Nuplazid
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
US Approval For ViiV’s ‘Last Resort’ HIV Drug Rukobia
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Need a specific report? 1000+ reports available
Buy Reports